SCM
EPZM

Shapiro Capital Management’s Epizyme, Inc EPZM Stock Holding History

Shapiro Capital Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-9,940
Closed -$280K – 65
2013
Q2 		$280K Buy
+9,940
New +$255K 0.01% 59

Other funds holding EPZM

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Shapiro Capital Management's EPZM Position: Q3 2013 in Review

Shapiro Capital Management sold out of Epizyme, Inc (EPZM) in Q3 2013, closing a stake of 9,940 shares — an estimated $280K sold.

Shapiro Capital Management first reported a position in EPZM in Q2 2013 and held it in 1 quarter. The position peaked at $280K in Q2 2013. 67 funds tracked by Wall St. Rank hold EPZM as of Q3 2013.

  • Shapiro Capital Management reported no remaining Epizyme, Inc position as of Q3 2013 after selling out during the quarter.
  • Shapiro Capital Management sold 9,940 Epizyme, Inc shares in Q3 2013, an estimated $280K.
  • Shapiro Capital Management first reported a position in Epizyme, Inc in Q2 2013 and held it in 1 quarter.
  • Shapiro Capital Management's Epizyme, Inc position peaked at $280K in Q2 2013.
  • 67 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2013.

Based on Shapiro Capital Management's 13F filing for Q3 2013, filed 14 Nov 2013.